logo-loader
viewAstraZeneca

AstraZeneca gets US regulatory green light for slow-release diabetes drug

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control

green traffic light
America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials

AstraZeneca PLC (LON:AZN) has received the US regulatory green light for a slow-release version of its type-2 diabetes treatment.

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control.

America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials.

Quick facts: AstraZeneca

Price: 7254 GBX

LSE:AZN
Market: LSE
Market Cap: £95.17 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Eckoh PLC doubles its US revenues with 'more to come', says...

Eckoh PLC's (LON:ECK) Nik Philpot talks Proactive through their results for the six months to September 2019. The group enjoyed significant commercial traction in the US, where revenues doubled and, since period end, they've landed a deal with an unnamed Fortune 100 retailer. For the group...

13 hours, 51 minutes ago

2 min read